As of September 18, 2026, ZYDUSLIFE is trading at ₹1160.0, showing a mixed technical picture across different timeframes. The daily and weekly timeframes indicate a bullish trend, with prices trading above key moving averages (EMA 20, EMA 50, SMA 20, SMA 50, SMA 200) and the Supertrend indicator. However, the monthly timeframe presents a conflicting bearish signal, with the price below the monthly Supertrend. Recent market activity includes two positive attention events in the last 30 days, with a moderate upward price movement accompanied by higher volume on September 18, 2026.

The stock is currently positioned within its recent trading range, with the price sitting above the 20-day and 50-day range positions but below the 252-day range position. Nearest support is identified at ₹1149.97, followed by ₹1125.03. Resistance is observed at ₹1164.83 and ₹1171.65. The stock exhibits an annualized volatility of 24% and a current drawdown of -4%, with a maximum drawdown of -19% observed historically. The presence of a "Morning Star" pattern on the weekly chart and a "Doji" on the monthly chart suggest potential indecision or reversal signals.

Key watch conditions include monitoring the price action around the ₹1164.83 resistance level. A sustained move above this level, especially with increased volume, could strengthen the bullish short-to-medium term outlook. Conversely, a break below the ₹1149.97 support level, particularly if accompanied by rising volume, might indicate further downside pressure, aligning with the bearish monthly trend signal.

As of September 18, 2026, Zydus Lifesciences (ZYDUSLIFE) on the NSE has seen its stock price increase to ₹1160.0 from a previous price of ₹1135.1. This represents a recent upward movement in the stock's valuation. The company's profile and listing on the NSE remain consistent with prior context. No new filings or news developments were reported as of the observation date.

Zydus Lifesciences Limited announced on August 31, 2026, positive topline results from its completed EVIDENCES-X Phase II(b) clinical trial for Saroglitazar Mg in MASH. This development is significant as it pertains to the potential efficacy of a new drug candidate. The company also disclosed on August 26, 2026, its intention to acquire companies that are yet to be incorporated, which could indicate future expansion or strategic initiatives. Additionally, on September 11, 2026, the company informed the exchange about an upcoming schedule of meetings with analysts and institutional investors, and also about its credit rating, which are standard updates for listed entities.

Zydus Lifesciences (NSE) reported its financial results for the periods ending Q3 FY2025-26, Q4 FY2025-26, and Q1 FY2026-27. Revenue from operations showed an upward trend, increasing from ₹6,864.50 crore in Q3 FY2025-26 to ₹8,017 crore in Q1 FY2026-27. However, expenses also rose significantly, particularly in Q1 FY2026-27, reaching ₹6,798.30 crore compared to ₹5,537.60 crore in Q3 FY2025-26. This rise in expenses impacted profitability. Profit Before Exceptional Items And Tax saw fluctuations, peaking at ₹2,057.20 crore in Q4 FY2025-26 before declining to ₹1,324.80 crore in Q1 FY2026-27. Similarly, Profit Loss For Period decreased from ₹1,341 crore in Q4 FY2025-26 to ₹990.20 crore in Q1 FY2026-27. The profit from continuing operations followed a similar pattern, decreasing to ₹952.40 crore in Q1 FY2026-27 from ₹1,341.30 crore in Q4 FY2025-26. Investors may want to monitor the company's expense management and its impact on profit margins in upcoming quarters.

The company's stock is exhibiting several constructive technical signals across different timeframes as of September 18, 2026. On a daily basis, the Supertrend indicator is bullish, and the 20-day Exponential Moving Average (EMA) shows a positive slope, suggesting upward momentum. This is further supported by a bullish Supertrend direction on the weekly timeframe, with both the 20-day and 50-day Simple Moving Averages (SMA) trending upwards. The stock has also demonstrated positive returns over various periods, including a 29% return in the last six months and a 27% year-to-date return, indicating recent market appreciation.

The company's monthly technical trend indicates a bearish signal, with the Supertrend indicator at ₹1167.31 suggesting a potential downward movement. This is further supported by a monthly ADX of 31.78, which can signify strong trending conditions, though the direction is indicated as bearish. While the daily trend shows a bullish Supertrend at ₹1091.06, the monthly perspective warrants caution. The stock is trading near its nearest resistance level of ₹1164.83, with a distance of 0.42%. Additionally, the company has experienced a maximum drawdown of -19%, indicating past periods of significant decline.